CD83 and Hodgkins lymphoma: Novel pieces of evidence in favor of the notion that CD83 is an emerging therapeutic target for cancer cells are as follows: (i) melanoma cells with enforced expression of CD83 induce antitumor immunity [39]; (ii) anti-human CD83 antibody with toxin monomethyl auristatin E conjugate kills CD83-positive Hodgkin lymphoma tumor cells [31].